A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)
The E-VITA study evaluated the efficacy and tolerability of two schedules of eribulin and lapatinib in patients with trastuzumab-pretreated HER-2-positive metastatic breast cancer. This multicenter, open-label phase II trial, randomly assigned patients with trastuzumab-pretreated HER-2-positive meta...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
APR 2019
|
| In: |
Anti-cancer drugs
Year: 2019, Jahrgang: 30, Heft: 4, Pages: 394-401 |
| ISSN: | 1473-5741 |
| DOI: | 10.1097/CAD.0000000000000722 |
| Online-Zugang: | Resolving-System, Volltext: https://dx.doi.org/10.1097/CAD.0000000000000722
|
| Verfasserangaben: | Joachim Bischoff, Jana Barinoff, Christoph Mundhenke, Dirk O. Bauerschlag, Serban-Dan Costa, Daniel Herr, Kristina Luebbe, Frederik Marme, Nicolai Maass, Gunter von Minckwitz, Eva-Maria Grischke, Volkmar Mueller, Marcus Schmidt, Bernd Gerber, Sherko Kuemmel, Claudia Schumacher, Petra Krabisch, Sabine Seiler, Marc Thill, Valentina Nekljudova, Sibylle Loibl |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1664969225 | ||
| 003 | DE-627 | ||
| 005 | 20230426130907.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190508s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/CAD.0000000000000722 |2 doi | |
| 035 | |a (DE-627)1664969225 | ||
| 035 | |a (DE-599)KXP1664969225 | ||
| 035 | |a (OCoLC)1341212570 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Bischoff, Joachim |e VerfasserIn |0 (DE-588)1043621083 |0 (DE-627)770729576 |0 (DE-576)395160359 |4 aut | |
| 245 | 1 | 2 | |a A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA) |c Joachim Bischoff, Jana Barinoff, Christoph Mundhenke, Dirk O. Bauerschlag, Serban-Dan Costa, Daniel Herr, Kristina Luebbe, Frederik Marme, Nicolai Maass, Gunter von Minckwitz, Eva-Maria Grischke, Volkmar Mueller, Marcus Schmidt, Bernd Gerber, Sherko Kuemmel, Claudia Schumacher, Petra Krabisch, Sabine Seiler, Marc Thill, Valentina Nekljudova, Sibylle Loibl |
| 264 | 1 | |c APR 2019 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 08.05.2019 | ||
| 520 | |a The E-VITA study evaluated the efficacy and tolerability of two schedules of eribulin and lapatinib in patients with trastuzumab-pretreated HER-2-positive metastatic breast cancer. This multicenter, open-label phase II trial, randomly assigned patients with trastuzumab-pretreated HER-2-positive metastatic breast cancer to lapatinib 1000 mg daily with eribulin 1.23 mg/m(2) (equivalent to 1.4 mg/m(2) eribulin mesylate) days 1+8 every 21 days (split-dose arm) or eribulin 1.76 mg/m(2) (equivalent to 2.0 mg/m(2) eribulin mesylate) day 1 every 21 days (3-weekly arm). Time to progression and tolerability were defined as primary end points; no sample size calculation for formal comparison of efficacy data has been performed. Secondary end points included objective response rate, clinical benefit rate, and overall survival. Overall, 43 patients of a planned number of 80 patients were recruited. At a median follow-up of 28.7 months, the median time to progression was 8.1 months [95% confidence interval (CI): 4.8-9.4] in the split-dose arm and 6.5 months (95% CI: 4.6-13.4) in the 3-weekly arm. Objective response rate was 52.4% (95% CI: 31.0-73.7) in the split-dose arm and 45.0% (95% CI: 23.2-66.8) in the 3-weekly arm, and clinical benefit rate was 71.4% (95% CI: 52.1-90.8) and 75.0% (95% CI: 56.0-94.0), respectively. Overall survival was also similar in both arms. The most frequent grade 3-4 adverse events were neutropenia (58.5%) and leukopenia (39.0%). The combination of eribulin and lapatinib showed an acceptable safety profile with less toxicity observed in the eribulin 1.23 mg/m(2) day 1+8 group. This might be an alternative regimen when other treatment options are exhausted. Therefore, further clinical studies are warranted. | ||
| 650 | 4 | |a anthracycline | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a capecitabine | |
| 650 | 4 | |a emtansine | |
| 650 | 4 | |a eribulin | |
| 650 | 4 | |a halichondrin b analog | |
| 650 | 4 | |a HER-2-positive | |
| 650 | 4 | |a japanese patients | |
| 650 | 4 | |a lapatinib | |
| 650 | 4 | |a mesylate | |
| 650 | 4 | |a monotherapy | |
| 650 | 4 | |a open-label | |
| 650 | 4 | |a physicians choice | |
| 650 | 4 | |a survival | |
| 700 | 1 | |a Barinoff, Jana |d 1970- |e VerfasserIn |0 (DE-588)1011315858 |0 (DE-627)658457756 |0 (DE-576)341291994 |4 aut | |
| 700 | 1 | |a Mundhenke, Christoph |d 1970- |e VerfasserIn |0 (DE-588)12010685X |0 (DE-627)080450482 |0 (DE-576)292045034 |4 aut | |
| 700 | 1 | |a Bauerschlag, Dirk Olaf |d 1972- |e VerfasserIn |0 (DE-588)123461022 |0 (DE-627)082568626 |0 (DE-576)293718504 |4 aut | |
| 700 | 1 | |a Costa, Serban-Dan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Herr, Daniel |e VerfasserIn |0 (DE-588)130489352 |0 (DE-627)629947732 |0 (DE-576)190020768 |4 aut | |
| 700 | 1 | |a Lübbe, Kristina |d 1969- |e VerfasserIn |0 (DE-588)121352870 |0 (DE-627)70540529X |0 (DE-576)292664974 |4 aut | |
| 700 | 1 | |a Marmé, Frederik |d 1974- |e VerfasserIn |0 (DE-588)132561972 |0 (DE-627)52394893X |0 (DE-576)299226549 |4 aut | |
| 700 | 1 | |a Maass, Nicolai |d 1964- |e VerfasserIn |0 (DE-588)141949716 |0 (DE-627)632148543 |0 (DE-576)189122889 |4 aut | |
| 700 | 1 | |a Minckwitz, Gunter von |d 1964- |e VerfasserIn |0 (DE-588)172260035 |0 (DE-627)673296962 |0 (DE-576)133128202 |4 aut | |
| 700 | 1 | |a Grischke, Eva-Maria |e VerfasserIn |0 (DE-588)1052608183 |0 (DE-627)788771698 |0 (DE-576)408382872 |4 aut | |
| 700 | 1 | |a Müller, Volkmar |d 1967- |e VerfasserIn |0 (DE-588)12133497X |0 (DE-627)081238053 |0 (DE-576)292653719 |4 aut | |
| 700 | 1 | |a Schmidt, Marcus |e VerfasserIn |0 (DE-588)1016470517 |0 (DE-627)671325353 |0 (DE-576)352259922 |4 aut | |
| 700 | 1 | |a Gerber, Bernd |d 1957- |e VerfasserIn |0 (DE-588)136713238 |0 (DE-627)585337608 |0 (DE-576)301234620 |4 aut | |
| 700 | 1 | |a Kümmel, Sherko |d 1971- |e VerfasserIn |0 (DE-588)122704142 |0 (DE-627)082103372 |0 (DE-576)293388016 |4 aut | |
| 700 | 1 | |a Schumacher, Claudia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Krabisch, Petra |e VerfasserIn |4 aut | |
| 700 | 1 | |a Seiler, Sabine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thill, Marc |d 1969- |e VerfasserIn |0 (DE-588)120154129 |0 (DE-627)08048333X |0 (DE-576)292066694 |4 aut | |
| 700 | 1 | |a Nekljudova, Valentina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Loibl, Sibylle |e VerfasserIn |0 (DE-588)12433024X |0 (DE-627)085790508 |0 (DE-576)294122753 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anti-cancer drugs |d Hagerstown, Md. : Lippincott Williams & Wilkins, 1990 |g 30(2019), 4, Seite 394-401 |h Online-Ressource |w (DE-627)320649652 |w (DE-600)2025803-3 |w (DE-576)094502161 |x 1473-5741 |7 nnas |a A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA) |
| 773 | 1 | 8 | |g volume:30 |g year:2019 |g number:4 |g pages:394-401 |g extent:8 |a A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA) |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1097/CAD.0000000000000722 |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190508 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 132561972 |a Marmé, Frederik |m 132561972:Marmé, Frederik |d 910000 |d 910400 |e 910000PM132561972 |e 910400PM132561972 |k 0/910000/ |k 1/910000/910400/ |p 8 | ||
| 999 | |a KXP-PPN1664969225 |e 3472129115 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"id":{"zdb":["2025803-3"],"issn":["1473-5741"],"eki":["320649652"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"320649652","disp":"A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)Anti-cancer drugs","type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.1990 -"],"note":["Gesehen am 17.10.05"],"origin":[{"publisherPlace":"Hagerstown, Md. ; [Erscheinungsort nicht ermittelbar]","dateIssuedKey":"1990","publisher":"Lippincott Williams & Wilkins ; Ovid","dateIssuedDisp":"1990-"}],"title":[{"title":"Anti-cancer drugs","title_sort":"Anti-cancer drugs"}],"part":{"text":"30(2019), 4, Seite 394-401","issue":"4","year":"2019","pages":"394-401","extent":"8","volume":"30"},"language":["eng"]}],"recId":"1664969225","name":{"displayForm":["Joachim Bischoff, Jana Barinoff, Christoph Mundhenke, Dirk O. Bauerschlag, Serban-Dan Costa, Daniel Herr, Kristina Luebbe, Frederik Marme, Nicolai Maass, Gunter von Minckwitz, Eva-Maria Grischke, Volkmar Mueller, Marcus Schmidt, Bernd Gerber, Sherko Kuemmel, Claudia Schumacher, Petra Krabisch, Sabine Seiler, Marc Thill, Valentina Nekljudova, Sibylle Loibl"]},"physDesc":[{"extent":"8 S."}],"id":{"eki":["1664969225"],"doi":["10.1097/CAD.0000000000000722"]},"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"APR 2019"}],"note":["Gesehen am 08.05.2019"],"title":[{"title":"A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)","title_sort":"randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"person":[{"role":"aut","given":"Joachim","family":"Bischoff","display":"Bischoff, Joachim"},{"given":"Jana","role":"aut","display":"Barinoff, Jana","family":"Barinoff"},{"display":"Mundhenke, Christoph","family":"Mundhenke","given":"Christoph","role":"aut"},{"family":"Bauerschlag","display":"Bauerschlag, Dirk Olaf","role":"aut","given":"Dirk Olaf"},{"role":"aut","given":"Serban-Dan","family":"Costa","display":"Costa, Serban-Dan"},{"given":"Daniel","role":"aut","display":"Herr, Daniel","family":"Herr"},{"display":"Lübbe, Kristina","family":"Lübbe","given":"Kristina","role":"aut"},{"role":"aut","given":"Frederik","family":"Marmé","display":"Marmé, Frederik"},{"given":"Nicolai","role":"aut","family":"Maass","display":"Maass, Nicolai"},{"role":"aut","given":"Gunter von","display":"Minckwitz, Gunter von","family":"Minckwitz"},{"display":"Grischke, Eva-Maria","family":"Grischke","given":"Eva-Maria","role":"aut"},{"display":"Müller, Volkmar","family":"Müller","role":"aut","given":"Volkmar"},{"family":"Schmidt","display":"Schmidt, Marcus","role":"aut","given":"Marcus"},{"given":"Bernd","role":"aut","family":"Gerber","display":"Gerber, Bernd"},{"family":"Kümmel","display":"Kümmel, Sherko","role":"aut","given":"Sherko"},{"display":"Schumacher, Claudia","family":"Schumacher","role":"aut","given":"Claudia"},{"given":"Petra","role":"aut","display":"Krabisch, Petra","family":"Krabisch"},{"role":"aut","given":"Sabine","family":"Seiler","display":"Seiler, Sabine"},{"family":"Thill","display":"Thill, Marc","role":"aut","given":"Marc"},{"display":"Nekljudova, Valentina","family":"Nekljudova","role":"aut","given":"Valentina"},{"role":"aut","given":"Sibylle","display":"Loibl, Sibylle","family":"Loibl"}]} | ||
| SRT | |a BISCHOFFJORANDOMIZED2019 | ||